Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genes
Concurrent $155 million PIPE financing is backed by leading life science investors led by Acuta Capital Partners and KVP Capital and including Avoro Capital Advisors; Avoro Ventures; Venrock Healthcare Capital ... Read More
Latest News
11
Jan2021
EOC Pharma acquires exclusive development and commercialization rights to ABI-009 in Greater China
Aadi will receive an upfront payment, regulatory and sales milestone payments totaling up to $271M plus royalties
Aadi Bioscience (Aadi), a biopharmaceutical company focusing on precision therapies for genomically defined cancers and EOC Pharma (EOC), a leading oncology specialty ... Read More
January 11, 2021admin
20
Nov2020
25
Jun2020
Rolling submission of U.S. FDA New Drug Application initiated
Long-term follow-up data released at ASCO 2020 for AMPECT study
Independent reviewed ORR of 39%
Long-term, durable ongoing responses with half the responders having ongoing response duration of 25.8 months or longer
Exploratory analysis in patients with TSC2 mutated tumors show ... Read More
June 25, 2020admin
20
Jun2020
20
Jun2020
24
Nov2019
20
Nov2019
14
Nov2019
Business Wire article link: Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Preliminary Data Released from the AMPECT Registration Trial in Advanced PEComa
Highlights:
Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy
First prospective clinical study in advanced ... Read More
November 14, 2019admin